These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36201738)

  • 21. Exploring pharmacists' opinions regarding PHARMAC's interventions in promoting brand changes.
    Babar ZU; Polwin A; Kan SW; Amerasinghe N; McCarthy S; Rasheed F; Stewart J; Lessing C; Ragupathy R; Scahill SL
    Res Social Adm Pharm; 2015; 11(1):96-110. PubMed ID: 24811426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identifying priority medicines policy issues for New Zealand: a general inductive study.
    Babar ZU; Francis S
    BMJ Open; 2014 May; 4(5):e004415. PubMed ID: 24871535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Key informants' perceptions of how pharmac operates in New Zealand.
    Ragupathy R; Tordoff J; Norris P; Reith D
    Int J Technol Assess Health Care; 2012 Oct; 28(4):367-73. PubMed ID: 23062515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of centrally developed pharmacoeconomic assessments for local formulary decisions.
    Tordoff JM; Murphy JE; Norris PT; Reith DM
    Am J Health Syst Pharm; 2006 Sep; 63(17):1613-8. PubMed ID: 16914631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pricing strategies, executive committee power and negotiation leverage in New Zealand's containment of public spending on pharmaceuticals.
    Main B; Csanadi M; Ozieranski P
    Health Econ Policy Law; 2022 Jul; 17(3):348-365. PubMed ID: 35382921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PHARMAC and the statin debacle.
    Ellis C; White H
    N Z Med J; 2006 Jun; 119(1236):U2033. PubMed ID: 16807576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health economic assessment: cost-effectiveness thresholds and other decision criteria.
    Simoens S
    Int J Environ Res Public Health; 2010 Apr; 7(4):1835-40. PubMed ID: 20617062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comments on "Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966"-New Zealand in fact has no cost-effectiveness threshold.
    Metcalfe S; Grocott R
    Int J Environ Res Public Health; 2010 Apr; 7(4):1831-4. PubMed ID: 20617061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of mandatory folate fortification v. other options for the prevention of neural tube defects: results from Australia and New Zealand.
    Dalziel K; Segal L; Katz R
    Public Health Nutr; 2010 Apr; 13(4):566-78. PubMed ID: 19758481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
    Panattoni L; Brown PM; Te Ao B; Webster M; Gladding P
    Pharmacoeconomics; 2012 Nov; 30(11):1067-84. PubMed ID: 22974536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Environmental cost of using poor decision metrics to prioritize environmental projects.
    Pannell DJ; Gibson FL
    Conserv Biol; 2016 Apr; 30(2):382-91. PubMed ID: 26365219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decision making the explicit evidence-based way: comparing benefits, harms and costs.
    McArthur J; Dickinson A
    Nurs Prax N Z; 1999 Mar; 14(1):33-42. PubMed ID: 10481662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Cost-Effectiveness Analysis Comparing Clinical Decision Rules PECARN, CATCH, and CHALICE With Usual Care for the Management of Pediatric Head Injury.
    Dalziel K; Cheek JA; Fanning L; Borland ML; Phillips N; Kochar A; Dalton S; Furyk J; Neutze J; Dalziel SR; Lyttle MD; Bressan S; Donath S; Molesworth C; Hearps SJC; Oakley E; Babl FE;
    Ann Emerg Med; 2019 May; 73(5):429-439. PubMed ID: 30447947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health economics and health technology assessment: perspectives from Australia and New Zealand.
    Streat S; Munn S
    Crit Care Clin; 2012 Jan; 28(1):125-33, vii. PubMed ID: 22123104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health economics: a framework for health service decision-making.
    Bowie RD
    N Z Med J; 1991 Mar; 104(907):99-102. PubMed ID: 1900927
    [No Abstract]   [Full Text] [Related]  

  • 36. PHARMAC Mark 2: towards agreed solutions?
    Bosanquet N
    N Z Med J; 2000 Oct; 113(1119):409-10. PubMed ID: 11127353
    [No Abstract]   [Full Text] [Related]  

  • 37. Health economics and health policy: experiences from New Zealand.
    Cumming J
    Appl Health Econ Health Policy; 2015 Jun; 13(3):281-9. PubMed ID: 25583117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overheard conversation between Phaedrus (a clinician) and Communocrat (a community physician).
    N Z Med J; 1980 Apr; 91(657):263. PubMed ID: 6771725
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
    Carswell C; Wheeler A; Vanderpyl J; Robinson E
    Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-Market Values in a Cost-Benefit World: Evidence from a Choice Experiment.
    Eppink FV; Winden M; Wright WC; Greenhalgh S
    PLoS One; 2016; 11(10):e0165365. PubMed ID: 27783657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.